- RON76.69m
- RON225.07m
- RON1.12bn
- 33
- 99
- 43
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.43 | ||
| Price to Free Cashflow | 2.95 | ||
| Price to Sales | 0.06 | ||
| EV to EBITDA | 4.43 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.08% | ||
| Return on Equity | 0.01% | ||
| Operating Margin | 1.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | RONm | 788.92 | 810.89 | 890.27 | 1,004.85 | 1,122.41 | n/a | n/a | 11.84% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -35.68 | -8.67 | +47.3 | -27.68 | +5.49 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ropharma SA is a Romania-based company engaged in the pharmaceutical industry. The Company is active in the wholesale and retail of drugs. It also has a production facility of over-the-counter drugs and dietary supplements. The Company sells pharmaceutical products through its pharmacies located in the Romanian cities of Iasi, Vaslui, Suceava, Botosani, Bacau, Neamt, Vrancea, Mures, Harghita, Sibiu and Brasov. Through its distribution center, the Company provides drugs, food supplements, skin cosmetics and other products. It manufactures pharmaceutical products under the brand names Aesculap, Bioef and Eurofarmaco. As of December 31, 2011, Ropharma SA had six subsidiaries: Romanita-Farm Srl, Ropharma Production Srl, Aesculap Prod Srl, Ergo Farm Srl, Drops Farm Srl and Europharm Trading 7 SA.
Directors
- Mihai Miron CHM (58)
- Alin Radasanu CFO (46)
- Danut Ene DHR (50)
- Mihai Bratescu DRC (53)
- Doru Darabus DRC (57)
- Florentina Miron DRC (63)
- Ovidiu Nut DRC (58)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- October 25th, 2007
- Public Since
- January 13th, 1997
- No. of Employees
- 1,353
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
Bucharest Stock Exchange- Shares in Issue
- 511,267,413
- Address
- Str. Iuliu Maniu, Nr. 55, Etaj 1, BRASOV, 500091
- Web
- https://ropharma.ro/
- Phone
- +40 268547233
- Auditors
- Mazars Romania S.R.L.
Upcoming Events for RPH
Similar to RPH
Alcom SA
Bucharest Stock Exchange
Alimentara SA
Bucharest Stock Exchange
Bucur SA
Bucharest Stock Exchange
Comaliment Resita Sa
Bucharest Stock Exchange
Comturist SA
Bucharest Stock Exchange
FAQ
As of Today at 22:59 UTC, shares in Ropharma SA are trading at RON0.15. This share price information is delayed by 15 minutes.
Shares in Ropharma SA last closed at RON0.15 and the price had moved by -19.35% over the past 365 days. In terms of relative price strength the Ropharma SA share price has underperformed the FTSE Global All Cap Index by -21.37% over the past year.
The overall consensus recommendation for Ropharma SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreRopharma SA does not currently pay a dividend.
Ropharma SA does not currently pay a dividend.
Ropharma SA does not currently pay a dividend.
To buy shares in Ropharma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of RON0.15, shares in Ropharma SA had a market capitalisation of RON76.69m.
Here are the trading details for Ropharma SA:
- Country of listing: Romania
- Exchange: BUH
- Ticker Symbol: RPH
Based on an overall assessment of its quality, value and momentum Ropharma SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ropharma SA is RON0.18. That is 20% above the last closing price of RON0.15.
Analysts covering Ropharma SA currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ropharma SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -14.88%.
As of the last closing price of RON0.15, shares in Ropharma SA were trading -12.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ropharma SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at RON0.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ropharma SA's management team is headed by:
- Mihai Miron - CHM
- Alin Radasanu - CFO
- Danut Ene - DHR
- Mihai Bratescu - DRC
- Doru Darabus - DRC
- Florentina Miron - DRC
- Ovidiu Nut - DRC